# A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

> **NCT07041099** · PHASE1 · RECRUITING · sponsor: **Cullinan Therapeutics Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Sjögren
- Sjogren Disease
- Sjogren's Syndrome

## Interventions

- **DRUG:** CLN-978

## Key facts

- **NCT ID:** NCT07041099
- **Lead sponsor:** Cullinan Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2028-03-15
- **Final completion:** 2029-03-15
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07041099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07041099, "A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07041099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*